Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER-HFpEF: Ulacamten in Symptomatic HFpEF
NCT06793371Phase 2Recruiting
- Sponsor
- Cytokinetics
- Start
- Feb 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ck-586 in heart failure with preserved ejection fraction (HFpEF), sponsored by Cytokinetics. Started Feb 2025; status: recruiting.
02
Drugs
ck-586
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06793371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793371.